Prenatal screening history

1980 – 1990
Pioneering the foundation

Early discoveries and breakthrough assays laid the foundation for modern prenatal screening.

Early 1980
AFP testing for neural tube defects

Revvity begins its prenatal journey.



1984
Low AFP linked to Down syndrome

Professors Cuckle and Wald's discovery pioneers a new era in screening.

1986+
Partnerships that drive innovation

Long-standing collaboration with key opinion leaders begins.

1990
Expanding the screening portfolio

- PAPP-A and free β-hCG assays launched
- AutoDELFIA system -the first for population screening
- Free ß-hCG adopted for second-trimester screening

2000 – 2010
Building industry leadership

Innovation in tools, software and partnerships to improve risk assessment.

2000
LifeCycle™ software launched

Risk calculation platform becomes widely adopted and continues to serve the field today.

2003
DELFIA™ Xpress launched

Enabling the One-Stop Clinic for Assessment of Risk (OSCAR) concept.



2008
Strengthening global partnerships

DELFIA™ Xpress installed at King's College Hospital, London (Harris Birthright Centre)

2010 – 2020
Expanding beyond aneuploidy

Addressing unmet clinical needs with breakthroughs in pre-eclampsia screening and global guidelines.

2010
PIGF assay launched

Early entrant in pre-eclampsia screening.

2011-2016
ASPRE study breakthrough

Second-generation PIGF 1-2-3 assay used in landmark trial screening 30,000+ women.

2018
International guidelines published

ISUOG (2018) and FIGO (2019) issue guidelines for pre-eclampsia screening.

2018
Vanadis™ system launched

Among the first NIPT platforms designed to be cost-effective enough to screen all women.



2021 – 2026
Global leadership and innovation

Advanced NIPT systems and a complete portfolio improving outcomes worldwide.

2022-2025
Global impact

Supporting national programs and expanding access across all continents, including China.

2026
Trusted partner for better outcomes

Complete portfolio of assays, platforms and software solutions that set industry standards.



40 Years

For in vitro diagnostic use. This product is only available where licensed in accordance with law.
Please contact your local representative for availability.

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.